On the other hand, phase I clinical trials of osimertinib combined with ABT-263 (Navitoclax) for patients with EGFR-mutated lung cancer after EGFR-TKI failure have been conducted, and dosing of osimertinib 80 mg daily and navitoclax 150 mg daily was well tolerated [37]. Here, EGFR is linked to lung cancer.